drugset / Trial / NCT01063036

Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment

NCT01063036

Phase 3 Completed 144 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to show that the combination of entecavir and tenofovir, is effective and well tolerated in chronic hepatitis B patients who have failed previous treatment.

Timeline

Start
2010-05
Primary completion
2012-11
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 1 mg Oral
Subject Tenofovir Small molecule 300 mg Oral